Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)
Parkinson Disease
Explore 241 assets in Parkinson Disease →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
TrueBinding, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06773962CT.gov A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) (this asset) | TrueBinding, Inc. | P2 | CCC · 53 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Other indications for Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2 | B · 58 |
| Ischemic Stroke | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-kappa-anti-homo-sapiens-lgals3-galectin-3-humanized-monoclonal-antibody-gamma4-heavy-chain-humanized-1-442-vh-homo-sapiens-ighv1-301-887-ighd-ighj601-933-cdr-imgt-889-26-3351-5897-105-1-116-homo-sapiens-ighg401-ng4ma-ch2-l92-g4v5-h-p10-ch1-117-214-hinge-1-12-s10p-224215-226-ch2-l92-305-227-336-ch3-337-441-chs-k2del-442-117-442-130-219-disulfide-with-kappa-light-chain-humanized-1-219-v-kappahomo-sapiens-igkv2d-2902-890-igkj201100-cdr-imgt-1139-27-3755-5794-102-1-112-homo-sapiens-igkc01-100-km3-a451158-v101-196-113-219-dimer-222-222225-225-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-glycoform-alfa-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →